Last reviewed · How we verify
Pneumovax 23- pneumococcal polysaccharide
Pneumovax 23, a pneumococcal polysaccharide vaccine marketed by the Mayo Clinic, holds a significant position in the prevention of pneumococcal disease. The key composition patent expires in 2028, providing a strong competitive advantage in maintaining market exclusivity. The primary risk is the potential for increased competition as the patent expiration approaches.
At a glance
| Generic name | Pneumovax 23- pneumococcal polysaccharide |
|---|---|
| Also known as | PPSV23 |
| Sponsor | Mayo Clinic |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumovax 23- pneumococcal polysaccharide CI brief — competitive landscape report
- Pneumovax 23- pneumococcal polysaccharide updates RSS · CI watch RSS
- Mayo Clinic portfolio CI